Sexually dimorphic dopaminergic dysfunction in a transgenic mouse model of Huntington's disease

Pharmacology Biochemistry and Behavior

Volumn 127, Issue , 2014, Pages 15-20

  Renoir, Thibault ^a   Argyropoulos, Andrew ^a   Chevarin, Caroline ^b,c   Lanfumey, Laurence ^b,c   Hannan, Anthony J ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b INSERM   (France)

^c SORBONNE UNIVERSITÉ   (France)

Author keywords

Bupropion; Dopamine; Huntington's disease; Locomotor activity; Sex differences; Tandem repeat disorder

Indexed keywords

6 CHLORO 2,3,4,5 TETRAHYDRO 7,8 DIHYDROXY 1 PHENYL 1H 3 BENZAZEPINE; AMFEBUTAMONE; DOPAMINE; DOPAMINE 1 RECEPTOR; DOPAMINE TRANSPORTER; 3,4-DIHYDROXYPHENYLACETIC ACID; DOPAMINE UPTAKE INHIBITORS; RECEPTORS, DOPAMINE D1;

ACUTE DRUG ADMINISTRATION; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC SYSTEM; DOSE RESPONSE; DRUG MEGADOSE; DRUG SENSITIVITY; EVIDENCE BASED PRACTICE; EXPLORATORY BEHAVIOR; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUNTINGTON CHOREA; IN VIVO STUDY; LOCOMOTION; MALE; MOUSE; NONHUMAN; SEX DIFFERENCE; TRANSGENIC MOUSE; TREATMENT RESPONSE; TURNOVER TIME; WILD TYPE; ANIMALS; ANTAGONISTS AND INHIBITORS; DISEASE MODELS, ANIMAL; GENETICS; HUNTINGTON DISEASE; METABOLISM; MICE; MICE, INBRED C57BL; MICE, INBRED CBA; MICE, TRANSGENIC; SEX CHARACTERISTICS;

3,4-DIHYDROXYPHENYLACETIC ACID; ANIMALS; DISEASE MODELS, ANIMAL; DOPAMINE; DOPAMINE UPTAKE INHIBITORS; FEMALE; HUNTINGTON DISEASE; MALE; MICE; MICE, INBRED C57BL; MICE, INBRED CBA; MICE, TRANSGENIC; RECEPTORS, DOPAMINE D1; SEX CHARACTERISTICS;

EID: 84908553434     PISSN: 00913057     EISSN: 18735177     Source Type: Journal    
DOI: 10.1016/j.pbb.2014.10.004     Document Type: Article

References (40)

1. Amsterdam JD, Newberg AB, Soeller I, Shults J. Greater striatal dopamine transporter density may be associated with major depressive episode. J Affect Disord 2012;141:425-31.
2. Andrews TC, Weeks RA, Turjanski N, Gunn RN, Watkins LH, Sahakian B, et al. Huntington's disease progression. PET and clinical observations. Brain 1999;122(Pt 12):2353-63.
3. Benn CL, Luthi-Carter R, Kuhn A, Sadri-Vakili G, Blankson KL, Dalai SC, et al. Environmental enrichment reduces neuronal intranuclear inclusion load but has no effect on messenger RNA expression in a mouse model of Huntington disease. J Neuropathol Exp Neurol 2010;69:817-27.
4. Bibb JA, Yan Z, Svenningsson P, Snyder GL, Pieribone VA, Horiuchi A, et al. Severe deficiencies in dopamine signaling in presymptomatic Huntington's disease mice. Proc Natl Acad Sci U S A 2000;97:6809-14.
5. Bjorkqvist M, Petersen A, Bacos K, Isaacs J, Norlen P, Gil J, et al. Progressive alterations in the hypothalamic-pituitary-adrenal axis in the R6/2 transgenic mouse model of Huntington's disease. Hum Mol Genet 2006;15:1713-21.
6. Bode FJ, Stephan M, Suhling H, Pabst R, Straub RH, Raber KA, et al. Sex differences in a transgenic rat model of Huntington's disease: decreased 17beta-estradiol levels correlate with reduced numbers of DARPP32+ neurons in males. Hum Mol Genet 2008;17:2595-609.
7. Cha JH, Kosinski CM, Kerner JA, Alsdorf SA, Mangiarini L, Davies SW, et al. Altered brain neurotransmitter receptors in transgenic mice expressing a portion of an abnormal human Huntington disease gene. Proc Natl Acad Sci U S A 1998;95:6480-5.
8. Cummings DM, Milnerwood AJ, Dallerac GM, Waights V, Brown JY, Vatsavayai SC, et al. Aberrant cortical synaptic plasticity and dopaminergic dysfunction in a mouse model of Huntington's disease. Hum Mol Genet 2006;15:2856-68.
9. Dallerac GM, Vatsavayai SC, Cummings DM, Milnerwood AJ, Peddie CJ, Evans KA, et al. Impaired long-term potentiation in the prefrontal cortex of Huntington's disease mouse models: rescue by D1 dopamine receptor activation. Neurodegener Dis 2011;8:230-9.
10. Dowie MJ, Bradshaw HB, Howard ML, Nicholson LF, Faull RL, Hannan AJ, et al. Altered CB1 receptor and endocannabinoid levels precede motor symptom onset in a transgenic mouse model of Huntington's disease. Neuroscience 2009;163:456-65.
11. Duchesne A, Dufresne MM, Sullivan RM. Sex differences in corticolimbic dopamine and serotonin systems in the rat and the effect of postnatal handling. Prog Neuropsychopharmacol Biol Psychiatry 2009;33:251-61.
12. Ginovart N, Lundin A, Farde L, Halldin C, Backman L, Swahn CG, et al. PET study of the preand post-synaptic dopaminergic markers for the neurodegenerative process in Huntington's disease. Brain 1997;120(Pt 3):503-14.
13. Glass M, van Dellen A, Blakemore C, Hannan AJ, Faull RL. Delayed onset of Huntington's disease in mice in an enriched environment correlates with delayed loss of cannabinoid CB1 receptors. Neuroscience 2004;123:207-12.
14. Grote HE, Bull ND, Howard ML, van Dellen A, Blakemore C, Bartlett PF, et al. Cognitive disorders and neurogenesis deficits in Huntington's disease mice are rescued by fluoxetine. Eur J Neurosci 2005;22:2081-8.
15. Hsiao MC, Lin KJ, Liu CY, Schatz DB. The interaction between dopamine transporter function, gender differences, and possible laterality in depression. Psychiatry Res 2013;211:72-7.
16. Johnson MA, Rajan V, Miller CE, Wightman RM. Dopamine release is severely compromised in the R6/2 mouse model of Huntington's disease. J Neurochem 2006;97:737-46.
17. Mandillo S, Golini E, Marazziti D, Di Pietro C, Matteoni R, Tocchini-Valentini GP. Mice lacking the Parkinson's related GPR37/PAEL receptor show non-motor behavioral phenotypes: age and gender effect. Genes Brain Behav 2013;12:465-77.
18. Mo C, Pang TY, Ransome MI, Hill RA, Renoir T, Hannan AJ. High stress hormone levels accelerate the onset of memory deficits in male Huntington's disease mice. Neurobiol Dis 2014;69:248-62.
19. Mochel F, Durant B, Durr A, Schiffmann R. Altered dopamine and serotonin metabolism in motorically asymptomatic R6/2 mice. PLoS One 2011;6:e18336.
20. Ortiz AN, Kurth BJ, Osterhaus GL, Johnson MA. Impaired dopamine release and uptake in R6/1 Huntington's disease model mice. Neurosci Lett 2011;492:11-4.
21. Ortiz AN, Osterhaus GL, Lauderdale K, Mahoney L, Fowler SC, von Horsten S, et al. Motor function and dopamine release measurements in transgenic Huntington's disease model rats. Brain Res 2012;1450:148-56.
22. Orvoen S, Pla P, Gardier AM, Saudou F, David DJ. Huntington's disease knock-inmalemice show specific anxiety-like behaviour and altered neuronal maturation. Neurosci Lett 2012;507:127-32.
23. Pang TY, Du X, Zajac MS, Howard ML, Hannan AJ. Altered serotonin receptor expression is associated with depression-related behavior in the R6/1 transgenic mouse model of Huntington's disease. Hum Mol Genet 2009;18:753-66.
24. Pavese N, Politis M, Tai YF, Barker RA, Tabrizi SJ, Mason SL, et al. Cortical dopamine dysfunction in symptomatic and premanifest Huntington's disease gene carriers. Neurobiol Dis 2010;37:356-61.
25. Petersen A, Puschban Z, Lotharius J, NicNiocaill B, Wiekop P, O'Connor WT, et al. Evidence for dysfunction of the nigrostriatal pathway in the R6/1 line of transgenic Huntington's disease mice. Neurobiol Dis 2002;11:134-46.
26. Pla P, Orvoen S, Saudou F, David DJ, Humbert S. Mood disorders in Huntington's disease: frombehavior to cellular andmolecular mechanisms. Front Behav Neurosci 2014;8:135.
27. Pouladi MA, Stanek LM, Xie Y, Franciosi S, Southwell AL, Deng Y, et al. Marked differences in neurochemistry and aggregates despite similar behavioural and neuropathological features of Huntington disease in the full-length BACHD and YAC128 mice. Hum Mol Genet 2012;21:2219-32.
28. Pouladi MA, Morton AJ, Hayden MR. Choosing an animal model for the study of Huntington's disease. Nat Rev Neurosci 2013;14:708-21.
29. Renoir T, Zajac MS, Du X, Pang TY, Leang L, Chevarin C, et al. Sexually dimorphic serotonergic dysfunction in a mouse model of Huntington's disease and depression. PLoS One 2011;6:e22133.
30. Renoir T, Pang TY, Zajac MS, Chan G, Du X, Leang L, et al. Treatment of depressive-like behaviour in Huntington's disease mice by chronic sertraline and exercise. Br J Pharmacol 2012;165:1375-89.
31. Reynolds GP, Dalton CF, Tillery CL, Mangiarini L, Davies SW, Bates GP. Brain neurotransmitter deficits inmice transgenic for the Huntington's diseasemutation. J Neurochem 1999;72:1773-6.
32. Spektor BS, Miller DW, Hollingsworth ZR, Kaneko YA, Solano SM, Johnson JM, et al. Differential D1 and D2 receptor-mediated effects on immediate early gene induction in a transgenic mouse model of Huntington's disease. Brain Res Mol Brain Res 2002; 102:118-28.
33. The Huntington's Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 1993;72:971-83.
34. Thompson TL1, Moss RL. Modulation of mesolimbic dopaminergic activity over the rat estrous cycle. Neurosci Lett 1997;229:145-8.
35. Thomsen M, Ralph RJ, Caine SB. Psychomotor stimulation by dopamine D(1)-like but not D(2)-like agonists in most mouse strains. Exp Clin Psychopharmacol 2011;19:342-60.
36. van Duijn E, Craufurd D, Hubers AA, Giltay EJ, Bonelli R, Rickards H, et al. Neuropsychiatric symptoms in a European Huntington's disease cohort (REGISTRY). J Neurol Neurosurg Psychiatry 2014. http://dx.doi.org/10.1136/jnnp-2013-307343. [Epub ahead of print].
37. Van Swearingen AE, Walker QD, Kuhn CM. Sex differences in novelty- and psychostimulant-induced behaviors of C57BL/6 mice. Psychopharmacology (Berl) 2013;225:707-18.
38. Weintraub D, Newberg AB, Cary MS, Siderowf AD, Moberg PJ, Kleiner-Fisman G, et al. Striatal dopamine transporter imaging correlates with anxiety and depression symptoms in Parkinson's disease. J Nucl Med 2005;46:227-32.
39. Yohrling GJ, Jiang GC, DeJohn MM, Miller DW, Young AB, Vrana KE, et al. Analysis of cellular, transgenic and human models of Huntington's disease reveals tyrosine hydroxylase alterations and substantia nigra neuropathology. Brain Res Mol Brain Res 2003; 119:28-36.
40. Yu L, Liao PC. Sexual differences and estrous cycle in methamphetamine-induced dopamine and serotonin depletions in the striatum of mice. J Neural Transm 2000;107: 419-27.